Stock EMMA EMMAUS LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Emmaus Life Sciences, Inc.

Equities

EMMA

US29137T1016

Market Closed - OTC Markets
Other stock markets
 19:18:25 24/06/2024 BST 		5-day change 1st Jan Change
0.091 USD 0.00% Intraday chart for Emmaus Life Sciences, Inc. -0.44% -9.09%
02-02 Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder) CI
2023 Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)
CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M
MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Emmaus Life Sciences, Inc Receives Marketing Authorization for Endari® in Oman
CI
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority
CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $6.8M
MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Emmaus Life Sciences, Inc. Receives Kuwaiti Marketing Authorization
CI
Emmaus Life Sciences, Inc. Receives Endari Marketing Authorization from the Qatar Ministry of Public Health
CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $3.2M
MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari
CI
Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology Annual Meeting
CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5.8M
MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EMMA Stock
  4. News Emmaus Life Sciences, Inc.
  5. Highlights